A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus

AIDS

Volumn 30, Issue 6, 2016, Pages 869-878

  Thompson, Melanie ^a   Saag, Michael ^b   Dejesus, Edwin ^c   Gathe, Joseph ^d   Lalezari, Jay ^e   Landay, Alan L ^f   Cade, Jerry ^g   Enejosa, Jeffrey ^h   Lefebvre, Eric ^h   Feinberg, Judith ⁱ  

^a AIDS Research Consortium of Atlanta   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c ORLANDO IMMUNOLOGY CENTER   (United States)

^d Therapeutic Concepts ^*  (United States)

^e Quest Clinical Research   (United States)

^f RUSH UNIVERSITY   (United States)

^g Nevada AIDS Research and Education Society   (United States)

^h Tobira Therapeutics Inc   (United States)

ⁱ UNIVERSITY OF CINCINNATI   (United States)

Author keywords

antiretroviral; C C chemokine receptor type 2 antagonist; C C chemokine receptor type 5 antagonist; cenicriviroc; HIV 1; randomized controlled trial

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD14 ANTIGEN; CD4 ANTIGEN; CENICRIVIROC; CHEMOKINE RECEPTOR CCR5; CREATINE KINASE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CHEMOKINE RECEPTOR CXCR5; CXCR5 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; IMMUNOLOGIC FACTOR; TAK-652; VIRUS RECEPTOR;

ABNORMAL DREAMING; ABNORMAL LABORATORY RESULT; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEDTIME DOSAGE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PUERTO RICO; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SUICIDAL IDEATION; TREATMENT DURATION; UNITED STATES; VIRUS MUTATION; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; CLINICAL TRIAL; COMPARATIVE STUDY; GENETICS; GENOTYPE; HIV INFECTIONS; ISOLATION AND PURIFICATION; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME; VIRAL TROPISM; VIRUS LOAD; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; IMIDAZOLES; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PUERTO RICO; RECEPTORS, CXCR5; RECEPTORS, HIV; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD; VIRAL TROPISM; YOUNG ADULT;

EID: 84960425749     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000988     Document Type: Article

References (21)

1. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviralnaive individuals. J Infect Dis 2005; 192: 466-474.
2. Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191: 866-872.
3. Shepherd JC, Jacobson LP, Qiao W, Jamieson BD, Phair JP, Piazza P, et al. Emergence and persistence of CXCR4-Tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis 2008; 198: 1104-1112.
4. Demarest J, Bonny T, Vavro C, Labranche C, Kitrinos K, McDanal C, et al. HIV-1 co-receptor tropism in treatment naive and experienced subjects. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 31 October 2004; Washington, District of Columbia, USA
5. Lalezari J, Gathe J, Brinson C, Thompson M, Cohen C, Dejesus E, et al. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. J Acquir Immune Defic Syndr 2011; 57: 118-125.
6. Miura K, Yang L, van Rooijen N, Ohnishi H, Seki E. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1310-G1321.
7. Saiman Y, Friedman SL. The role of chemokines in acute liver injury. Front Physiol 2012; 3: 213.
8. Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, Bursill CA, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest 2009; 119: 1858-1870.
9. Seki E, De Minicis S, Inokuchi S, Taura K, Miyai K, van Rooijen N, et al. CCR2 promotes hepatic fibrosis in mice. Hepatology 2009; 50: 185-197.
10. Aberg JA. Aging, inflammation, and HIV infection. Top Antivir Med 2012; 20: 101-105.
11. Lefebvre E, Hashiguchi T, Jenkins H, Nabhan A, Yoneyama H, Friedman SL, et al. Anti-fibrotic and anti-inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse model of NASH. Hepatology 2013; 58 (Suppl 1): 221A-222A.
12. Hong F, Chou H, Friedman SL. Significant antifibrotic activity of cenicriviroc, a dual CCR2/CCR5 antagonist, in a rat model of thioacetamide-induced liver fibrosis and cirrhosis. 64th Annual Meeting of the American Association of the Study of Liver Diseases (AASLD); 1 November 2013; Washington, District of Columbia, USA
13. Marier JF, Trinh M, Pheng LH, Palleja SM, Martin DE. Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naive patients. Antimicrob Agents Chemother 2011; 55: 2768-2774.
14. Bristol-Myers Squibb Pharma EEIG. Sustiva Summary of Product Characteristics. 2014.
15. Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr 2012; 60: 33-42.
16. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379: 2439-2448.
17. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369: 1807-1818.
18. Gatell JM, Morales-Ramirez JO, Hagins DP, Thompson M, Keikawus A, Hoffmann C, et al. Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients. J Int AIDS Soc 2014; 17: 19532.
19. Margolis DA, Brinson CC, Smith GH, de Vente J, Hagins DP, Eron JJ, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis 2015; 15: 1145-1155.
20. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780-790.
21. Moyle G, Richards TL, Plato CF, Jenkins H, Wolfgang GHI, Lefebvre E. Antifibrotic activity of dual CCR5/CCR2 antagonist cenicriviroc in a mouse model of renal fibrosis. 20th International AIDS Conference (AIDS 2014); 22 July 2014; Melbourne, Australia